Bibliography
- Rosenberg SA, Restifo NP, Yang JC, Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308
- Elinav E, Waks T, Eshhar Z. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice. Gastroenterology 2008;134:2014-24
- Pule MA, Savoldo B, Myers GD, Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14:1264-70
- Dudley ME, Wunderlich JR, Robbins PF, Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4
- Porter DL, Levine BL, Kalos M, Chimeric antigen receptor-modified T Cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33
- Kochenderfer JN, Wilson WH, Janik JE, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116:4099-110
- Eshhar Z. The T-body approach: redirecting T cells with antibody specificity. Handb Exp Pharmacol 2008(181):329-42
- Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009;21:215-23
- Dazzi F, Goldman JM. Adoptive immunotherapy following allogeneic bone marrow transplantation. Annu Rev Med 1998;49:329-40
- Zakrzewski JL, Suh D, Markley JC, Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol 2008;26:453-61
- Boni A, Muranski P, Cassard L, Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood 2008;112:4746-54
- Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 2005;23:127-59
- Matloubian M, Lo CG, Cinamon G, Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355-60
- Tedesco-Silva H, Szakaly P, Shoker A, FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. Transplantation 2007;84:885-92
- Kappos L, Antel J, Comi G, Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-40
- Taylor PA, Ehrhardt MJ, Lees CJ, Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). Blood 2007;110:3480-2488
- Marcus A, Waks T, Eshhar Z. Redirected tumor-specific allogeneic T cells for universal treatment of cancer. Blood 2011;118:975-83
- Hawkins RE, Gilham DE, Debets R, Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther 2010;21:665-72
- Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood 2008;112:2617-26
- Kaneko S, Mastaglio S, Bondanza A, IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 2009;113:1006-15
- Straathof KC, Pule MA, Yotnda P, An inducible caspase 9 safety switch for T-cell therapy. Blood 2005;105:4247-54